1. Home
  2. WWR vs RNXT Comparison

WWR vs RNXT Comparison

Compare WWR & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WWR
  • RNXT
  • Stock Information
  • Founded
  • WWR 1977
  • RNXT 2012
  • Country
  • WWR United States
  • RNXT United States
  • Employees
  • WWR N/A
  • RNXT N/A
  • Industry
  • WWR Metal Mining
  • RNXT Biotechnology: Pharmaceutical Preparations
  • Sector
  • WWR Basic Materials
  • RNXT Health Care
  • Exchange
  • WWR Nasdaq
  • RNXT Nasdaq
  • Market Cap
  • WWR 36.9M
  • RNXT 31.6M
  • IPO Year
  • WWR N/A
  • RNXT 2021
  • Fundamental
  • Price
  • WWR $1.04
  • RNXT $1.15
  • Analyst Decision
  • WWR
  • RNXT Strong Buy
  • Analyst Count
  • WWR 0
  • RNXT 1
  • Target Price
  • WWR N/A
  • RNXT $9.00
  • AVG Volume (30 Days)
  • WWR 938.1K
  • RNXT 195.7K
  • Earning Date
  • WWR 03-18-2025
  • RNXT 03-31-2025
  • Dividend Yield
  • WWR N/A
  • RNXT N/A
  • EPS Growth
  • WWR N/A
  • RNXT N/A
  • EPS
  • WWR N/A
  • RNXT N/A
  • Revenue
  • WWR N/A
  • RNXT N/A
  • Revenue This Year
  • WWR N/A
  • RNXT N/A
  • Revenue Next Year
  • WWR N/A
  • RNXT N/A
  • P/E Ratio
  • WWR N/A
  • RNXT N/A
  • Revenue Growth
  • WWR N/A
  • RNXT N/A
  • 52 Week Low
  • WWR $0.40
  • RNXT $0.77
  • 52 Week High
  • WWR $1.32
  • RNXT $1.86
  • Technical
  • Relative Strength Index (RSI)
  • WWR 49.66
  • RNXT 58.08
  • Support Level
  • WWR $0.86
  • RNXT $1.32
  • Resistance Level
  • WWR $1.32
  • RNXT $1.40
  • Average True Range (ATR)
  • WWR 0.11
  • RNXT 0.11
  • MACD
  • WWR -0.02
  • RNXT 0.00
  • Stochastic Oscillator
  • WWR 15.89
  • RNXT 39.47

About WWR Westwater Resources Inc.

Westwater Resources Inc focused on developing battery-grade natural graphite materials. The company is having one project which is the Westwater's coosa project which is currently used for the mining and extraction of graphite.

About RNXT RenovoRx Inc.

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

Share on Social Networks: